Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents

Marina G. Silveira, Keith Lindor

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting in advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After liver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.

Original languageEnglish (US)
Pages (from-to)425-443
Number of pages19
JournalClinics in Liver Disease
Volume12
Issue number2
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Cholagogues and Choleretics
Biliary Liver Cirrhosis
Immunosuppressive Agents
Ursodeoxycholic Acid
Liver Failure
Liver Diseases
Fibrosis
Intrahepatic Bile Ducts
Therapeutics
Life Expectancy
Liver Transplantation
Disease Progression
Transplantation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hepatology

Cite this

Treatment of Primary Biliary Cirrhosis : Therapy with Choleretic and Immunosuppressive Agents. / Silveira, Marina G.; Lindor, Keith.

In: Clinics in Liver Disease, Vol. 12, No. 2, 05.2008, p. 425-443.

Research output: Contribution to journalArticle

@article{1cf102eeb6794e509ba105209d33379a,
title = "Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents",
abstract = "Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting in advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After liver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.",
author = "Silveira, {Marina G.} and Keith Lindor",
year = "2008",
month = "5",
doi = "10.1016/j.cld.2008.02.008",
language = "English (US)",
volume = "12",
pages = "425--443",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment of Primary Biliary Cirrhosis

T2 - Therapy with Choleretic and Immunosuppressive Agents

AU - Silveira, Marina G.

AU - Lindor, Keith

PY - 2008/5

Y1 - 2008/5

N2 - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting in advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After liver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.

AB - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting in advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After liver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.

UR - http://www.scopus.com/inward/record.url?scp=43049083346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049083346&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2008.02.008

DO - 10.1016/j.cld.2008.02.008

M3 - Article

C2 - 18456189

AN - SCOPUS:43049083346

VL - 12

SP - 425

EP - 443

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 2

ER -